Data investigation
Where the Evidence Is Strongest
Most of what this register examines has something wrong with it. This does not: a synthesis of 13 trials rates the cardiovascular and kidney benefits in chronic kidney disease at high certainty.
Most of the evidence we examine has something wrong with it: heterogeneity, confounding, exploratory subgroups, thresholds barely cleared. This one is different. In people with chronic kidney disease, a synthesis of 13 trials (97,428 participants, 31,846 of them with confirmed CKD) rates the cardiovascular and kidney benefits at high certainty by GRADE,[1] the top of the scale. We have not been able to write that on this site before.
What the evidence shows
| Outcome | Effect | Certainty |
|---|---|---|
| Major adverse cardiovascular events | 16% reduction (HR 0.84, 95% CI 0.79–0.89) | High |
| Composite kidney endpoint | 21% reduction (HR 0.79, 0.73–0.86) | High |
| Kidney failure | 28% reduction (HR 0.72) | — |
| Urine albumin-to-creatinine ratio | 26% decrease | — |
| Acute kidney injury | No excess risk | — |
That last row matters more than it looks. The obvious mechanistic worry with these drugs in kidney disease is dehydration: vomiting and reduced fluid intake are exactly how someone with impaired kidneys ends up with acute injury. The concern is sensible, and it did not materialize.
The question every CKD patient actually has
Many people with chronic kidney disease and type 2 diabetes now take an SGLT2 inhibitor, which has its own strong kidney evidence. What taking both means day to day is in an SGLT2 and a GLP-1 together. So the practical question is less whether a GLP-1 works than whether it adds anything on top of what someone is already taking.
That one number does a lot of work. We covered a case where an interaction P of .06 left a clean-looking split unestablished, in the statistic that asks if groups differ, and a mirror case where values of 0.62, 0.40 and 0.99 showed subgroups behaving alike, in how many people to treat to help one. Here the same test answers a question with money and inconvenience riding on it, and the answer is that the benefit holds on top of an SGLT2 inhibitor.
What 'high certainty' means, and why it is unusual here
GRADE rates evidence on four levels (very low, low, moderate, high) based on risk of bias, consistency, directness, precision and publication bias. High means further research is very unlikely to change the estimate.
Almost nothing we have covered reaches it. The BMJ synthesis of 262 trials rated the newest drugs very low to low. The aspiration meta-analysis was low. The dose-withholding finding was very low. Set against that background, two high-certainty outcomes is a different kind of result.
A review that only ever discounts evidence is as useless as one that only ever promotes it.
The reason this particular question is well answered is not luck. It was studied in dedicated randomized trials, in a defined population, against hard endpoints such as dialysis, transplantation and death, which are counted rather than measured on a scale. That is what produces high certainty, and it is what most questions in this field have not had.
The one figure to hold loosely
The high-certainty finding is about the class. The ranking within it is not, and reading the SUCRA figure as “semaglutide is the best one for kidneys” would be taking the weakest number in the paper as its strongest.
For the trial that anchors this whole area, and the numbers needed to treat it produced, see how many people to treat to help one; for the broader kidney picture, GLP-1s and your kidneys.
Frequently Asked Questions
References
- 1.Kaur R, Singh A. Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis Diabetes, Obesity and Metabolism. 2026. PMID: 42337824.
Compare the sellers
Related research
How Many People to Treat to Help One
Trials report benefit as a percentage, which sounds impressive and tells you nothing about your own odds. FLOW published the number needed to treat instead: 22, 13 and 17 over three years.
7 min read
Tirzepatide vs Dulaglutide: A Real Head-to-Head
13,299 people randomized to one drug or the other, followed four years. Kidney events occurred in 6.0% on tirzepatide against 7.6% on dulaglutide, and nausea, vomiting and diarrhea were all more common on tirzepatide.
6 min read
Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1
SGLT2 inhibitors like Jardiance and Farxiga are routinely taken with Ozempic or Mounjaro, and no label forbids it. Sugar and weight effects add up in trials; heart and kidney gains rest on subgroups. The real overlap is dehydration and ketoacidosis.
12 min read
GLP-1s After a Kidney Transplant
A meta-analysis of 54,680 transplant recipients reports mortality nearly halved and kidney function improving. Four studies stand behind the mortality figure, and the size of the benefit is the reason to be careful with it.
6 min read
Does Weight Loss Fake Kidney Numbers?
Estimated kidney function is calculated from creatinine, and creatinine comes from muscle, so weight loss could flatter the number. A trial checked the estimates against a directly measured filtration rate.
7 min read
GLP-1 Drugs and Kidney Stones: What the Labels and Studies Show
No trial was designed to test whether Ozempic, Wegovy, Mounjaro or Zepbound cause kidney stones. Wegovy's label reports urinary stones in 1.2% vs 0.8% on placebo in a heart trial; the other labels are silent. What the cohorts, urine studies and fluid data show.
10 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HealthRX
Compounded semaglutide at $165/month after a $99 first month
From $165/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →